| Ultrarestrictive opioid prescription protocol for pain management after gynecologic and abdominal surgery J Mark, DM Argentieri, CA Gutierrez, K Morrell, K Eng, AD Hutson, ... JAMA network open 1 (8), e185452-e185452, 2018 | 123 | 2018 |
| Treatment of advanced malignant uterine perivascular epithelioid cell tumor with mTOR inhibitors: single-institution experience and review of the literature KD Starbuck, RD Drake, GT Budd, PG Rose Anticancer Research 36 (11), 6161-6164, 2016 | 52 | 2016 |
| Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies P Mayor, K Starbuck, E Zsiros Gynecologic oncology 150 (2), 361-369, 2018 | 38 | 2018 |
| Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: a National Cancer Database analysis JA Rauh-Hain, KD Starbuck, LA Meyer, J Clemmer, JO Schorge, KH Lu, ... Gynecologic oncology 139 (1), 84-89, 2015 | 37 | 2015 |
| The predominant WT1 isoform (+ KTS) encodes a DNA-binding protein targeting the planar cell polarity gene Scribble in renal podocytes J Wells, MN Rivera, WJ Kim, K Starbuck, DA Haber Molecular cancer research 8 (7), 975-985, 2010 | 33 | 2010 |
| History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report AN Minlikeeva, JL Freudenheim, RA Cannioto, KH Eng, JB Szender, ... British journal of cancer 117 (7), 1063-1069, 2017 | 25 | 2017 |
| Clinical needs for transgender men in the gynecologic oncology setting AE Stenzel, KB Moysich, CA Ferrando, KD Starbuck Gynecologic oncology, 2020 | 24 | 2020 |
| Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau K Starbuck, L Al-Alem, DA Eavarone, SF Hernandez, C Bellio, ... Oncotarget 9 (33), 23289, 2018 | 24 | 2018 |
| Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer KH Eng, K Morrell, K Starbuck, C Spring-Robinson, A Khan, D Cleason, ... Gynecologic oncology 146 (1), 52-57, 2017 | 21 | 2017 |
| Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization … G Mohapatra, DA Engler, KD Starbuck, JC Kim, DC Bernay, GA Scangas, ... Acta neuropathologica 121 (4), 529-543, 2011 | 14 | 2011 |
| Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer KD Starbuck, JB Szender, WD Duncan, K Morrell, JL Etter, E Zsiros, ... PloS one 13 (11), e0206913, 2018 | 12 | 2018 |
| Compositions and methods for targeting cancer stem cells DA Eavarone, J Behrens, JM Prendergast, BR Rueda, R Foster, ... US Patent App. 16/073,349, 2019 | 10 | 2019 |
| Anthropometric characteristics and ovarian cancer risk and survival AN Minlikeeva, KB Moysich, PC Mayor, JL Etter, RA Cannioto, RB Ness, ... Cancer Causes & Control 29 (2), 201-212, 2018 | 5 | 2018 |
| Implementation of a restrictive blood transfusion protocol in a gynecologic oncology service. J Mark, S Lynam, K Morrell, K Eng, K Starbuck, JB Szender, E Zsiros, ... Gynecology and reproductive endocrinology 3 (1), 1, 2019 | 4 | 2019 |
| Proton pump inhibitor use during chemotherapy for platinum-resistant or platinum-refractory ovarian cancer improves overall survival K Starbuck, S Belliotti, K Morrell, JL Etter, K Kolesnikova, E Zsiros, ... Gynecologic Oncology 149, 68, 2018 | 4 | 2018 |
| Compositions and methods for targeting cancer stem cells DA Eavarone, J DeSander, J Behrens, BR Rueda, R Foster, KD Starbuck US Patent App. 15/735,812, 2020 | 3 | 2020 |
| Novel oral small molecule CXCR4 inhibitor improves activity of immune checkpoint blockade in ovarian cancer mouse model K Starbuck, R McGray, S Masoumi-Moghaddam, A Francois, K Odunsi, ... Cancer Research 77 (13 Supplement), 956-956, 2017 | 3 | 2017 |
| TIGIT ligands CD155, CD112, and galectin-9 are associated with immune infiltration and increased overall survival in ovarian cancer K Starbuck, K Morrell, K Odunsi, E Zsiros, JB Szender, PJ Frederick, ... Gynecologic Oncology 149, 56, 2018 | 2 | 2018 |
| CXCR4 in combination with immune check point inhibition in ovarian cancer mouse model demonstrates potential for novel therapeutic strategies K Starbuck, R McGray, S Masoumi-Moghaddam, A Francois, K Odunsi, ... Cancer Research 77 (13 Supplement), 947-947, 2017 | 2 | 2017 |
| Multimodal therapy in the treatment of vaginal adenocarcinoma arising from endocervicosis K Starbuck, C Garcia, Q Wu, CD Runowicz Gynecologic oncology 120 (1), 158-159, 2011 | 2 | 2011 |
